MedTrace Logo

Quantification of the Dipeptidyl Peptidase (DPP)-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis

NCT00683735 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-12-18

No results posted yet for this study

Summary

Objective: To assess the effect if co-administration of sitagliptin and metformin compared to placebo on the incretin effect (based on the comparison of the insulin secretory response to oral glucose load and an 'isoglycaemic' intravenous glucose load). Hypothesis: Treatment with co-administration of sitagliptin and metformin provides a greater incretin effect compared to placebo.

Conditions

Interventions

DRUG

Sitagliptin

100 mg once daily in the morning

DRUG

Metformin

up to 2000 mg/day

DRUG

Placebo

500mg 1-0-0-0

DRUG

Placebo

100mg 1-0-0-0

Sponsors & Collaborators

  • Michael A. Nauck

    lead OTHER

Principal Investigators

  • Michael A. Nauck, Prof. Dr. · Diabeteszentrum Bad Lauterberg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2012-12-31
Completion
2013-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683735 on ClinicalTrials.gov